



BN/SB/08A/B

Substitute Form 1449A

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of 1

Complete if Known

Application Number	10/532,585
I.A. Filing Date	October 24, 2003
Filing Date	April 25, 2005
First Named Inventor	Kenshi KAMEI et al
Group Art Unit	1614
Examiner Name	P. G. Spavick
Attorney Docket Number	KAMEI=2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AE	US-6077943	06-20-2000	Omura et al	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
PS	AF	EP 1314737 A1	05-28-2003	CHUGAI SEIYAKU KABUSHIKI KAISHA		
PS	AG	WO 02/18403 A1	07-03-2002	CHUGAI SEIYAKU KABUSHIKI KAISHA		
	AH	WO 01/60833 A2	08-23-2001	KOSAN BIOSCIENCES INC.	duplicate	
PS	AI	JP 2001-118295	04-25-2000	TAKEDA CHEM IND LTD KITASATO INST:THE		
	AJ	WO 93/13780	07-22-1993	ABBOTT LABORATORIES (US:US); CHAD	duplicate	

Examiner
Signature

P. Spavick

Date
Considered

12/16/06

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.



BNVSB/08A/B

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/532,585
Filing Date	April 25, 2005
First Named Inventor	K. KAMEI et al
Group Art Unit	1614
Confirmation No.	4282
Attorney Docket Number	KAMEI=2

NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION

Examiner Initials*	Cita No.†	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
PS	AK	O. ALARADI et al; "Irritable bowel syndrome: update on pathogenesis and management"; <i>Med Principles Pract</i> ; Vol. 11, page 2-17, 2002.	
PS	AL	M. BRADETTE, et al; "Effect of motilin and erythromycin on the motor activity of the human colon"; <i>J. Gastrointest. Mot.</i> , Vol. 5, pages 247-251, 1993.	
PS	AM	D. M. CHIEPPA, et al; Effects of erythromycin on human colonic circular muscle in idiopathic chronic constipation"; <i>European Journal of Clinical Investigation</i> ; Vol. 30, pages 66-71, 2000.	
PS	AN	D. HARARI et al; "Correlates of regular laxative use by frail elderly persons"; <i>The American Journal of Medicine</i> , Vol. 99, pp. 513-518,	
PS	AO	Zen ITOH; "Motilin and Clinical Application"; <i>Peptides</i> , Vol. 18, No. 4, pages 593-608, 1997.	
PS	AP	J. S. JAMESON et al; "Oral or intravenous erythromycin has no effect on human distal colonic motility"; <i>Aliment, Pharmacol. Ther.</i> , Vol. 6, pages 589-595, 1992.	
PS	AQ	I.M.C. KAMERLING et al; "Dose-related effects of motilin on proximal gastrointestinal motility"; <i>Aliment Pharmacol Ther</i> ; Vol. 16, pages 129-135, 2002.	
PS	AR	I.M.C. KAMERLING et al; "Exogenous motilin affects postprandial proximal gastric motor function and visceral sensation"; <i>Digestive Diseases and Sciences</i> ; Vol. 47, No. 8, pages 1732-1736, 2002.	
PS	AS	H. KOGA et al; "Design, SAR and pharmacology of GM-611, the first acid-stable non-peptide motilin receptor agonist"; <i>Drugs of the Future</i> ; Vol. 27, No. 3; pages 255-272, 2002.	
PS	AT	Y.C. LUIKING et al; "Motilin induces gall bladder emptying and antral contractions in the fasted state in humans"; <i>Gut</i> ; Vol. 42, pages 830-835, 1998.	
PS	AU	M. PAPPAGALLO; "Incidence, Prevalence, and Management of Opioid Bowel Dysfunction"; <i>The American Journal of Surgery</i> ; Vol. 182, pages 11S-18S; 2001.	
PS	AV	S. SHARMA et al "Effect of oral erythromycin on colonic transit in patients with idiopathic constipation"; <i>Digestive Diseases and Sciences</i> , Vol. 40, No. 11, pages 2446-2449, 1995.	
PS	AW	D. THORPE; "Management of Opioid-induced Constipation"; <i>Curr. Pain Headache Rep.</i> , Vol. 5, pages 237-240, 2001.	

Examiner
Signature

P. Spwack

Date
Considered

12/16/06

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional). ‡ See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. § Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.